Published in Neuroendocrinology on December 12, 2007
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas (2010) 3.00
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2013) 2.27
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol (2008) 1.48
Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat Rev Endocrinol (2011) 1.35
Neuroendocrine tumors of the small bowels are on the rise: Early aspects and management. World J Gastrointest Endosc (2010) 1.33
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2009) 1.18
Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol (2009) 1.12
Neuroendocrine neoplasms of the gastrointestinal tract. Dtsch Arztebl Int (2011) 1.05
Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors. PLoS One (2010) 1.04
Chronic subacute bowel obstruction caused by carcinoid tumour misdiagnosed as irritable bowel syndrome: a case report. Cases J (2009) 0.98
Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy. Nanoscale (2012) 0.96
Diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors: current data on a prospectively collected, retrospectively analyzed clinical multicenter investigation. Oncologist (2011) 0.95
A multimodal approach to the management of neuroendocrine tumour liver metastases. Int J Hepatol (2012) 0.94
Surgical treatment of gastrointestinal neuroendocrine tumors. Langenbecks Arch Surg (2011) 0.93
Stenting of the superior mesenteric vein in midgut carcinoid disease with large mesenteric masses. World J Surg (2010) 0.91
Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review. Int J Hepatol (2011) 0.90
Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel. World J Gastroenterol (2010) 0.89
Contemporary methods of therapy and follow-up of neuroendocrine tumours of the gastrointestinal tract and the pancreas. Contemp Oncol (Pozn) (2012) 0.87
Autoregulatory effects of serotonin on proliferation and signaling pathways in lung and small intestine neuroendocrine tumor cell lines. Cancer (2009) 0.87
Neuroendocrine tumors arising in Meckel's diverticula: frequency of advanced disease warrants aggressive management. J Gastrointest Surg (2013) 0.85
Concurrent Occurrence of Tumor in Colon and Small Bowel following Intestinal Obstruction: A Case Report and Review of the Literature. Case Rep Surg (2016) 0.84
Quality of life, resource utilisation and health economics assessment in advanced neuroendocrine tumours: a systematic review. Eur J Cancer Care (Engl) (2013) 0.81
Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine. Eur J Nucl Med Mol Imaging (2015) 0.77
Advances in the diagnosis and treatment of pancreatic neuroendocrine neoplasms in Japan. J Gastroenterol (2016) 0.77
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour. Eur J Nucl Med Mol Imaging (2011) 0.77
Surgery for small-bowel neuroendocrine tumors: is there any benefit of the laparoscopic approach? Surg Endosc (2014) 0.76
A stepwise approach to the management of metastatic midgut carcinoid tumor. Nat Rev Clin Oncol (2009) 0.76
New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors. Gastroenterol Clin North Am (2010) 0.76
Synchronous association of rectal adenocarcinoma and three ileal carcinoids: a case report. World J Surg Oncol (2009) 0.75
Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget (2016) 0.75
New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future. World J Gastrointest Oncol (2017) 0.75
Endoscopic treatment of duodenal neuroendocrine tumors. Clin Endosc (2013) 0.75
Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol (2016) 0.75
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014. Curr Oncol (2015) 0.75
A wolf in sheep's clothing. BMJ Case Rep (2011) 0.75
Clinical features of gastroenteropancreatic tumours. Prz Gastroenterol (2015) 0.75
Medullary thyroid carcinoma and duodenal calcitonin-secreting neuroendocrine tumour: more than coincidence? Endocrinol Diabetes Metab Case Rep (2013) 0.75
Clinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver. Wien Klin Wochenschr (2016) 0.75
High-dose lanreotide in the treatment of poorly differentiated pancreatic neuroendocrine carcinoma: a case report. Case Rep Oncol (2014) 0.75
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia (2017) 0.75
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med (2017) 0.75
Neuroendocrine Tumor-Targeted Upconversion Nanoparticle-Based Micelles for Simultaneous NIR-Controlled Combination Chemotherapy and Photodynamic Therapy, and Fluorescence Imaging. Adv Funct Mater (2017) 0.75
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol (2008) 7.65
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56
Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. Arthritis Rheum (2012) 4.27
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology (2004) 3.70
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens. Virchows Arch (2004) 3.04
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2012) 3.00
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour/carcinoma of the appendix and goblet cell carcinoma. Neuroendocrinology (2007) 2.95
Feasibility and yield of a new EUS histology needle: results from a multicenter, pooled, cohort study. Gastrointest Endosc (2011) 2.82
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology (2006) 2.68
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch (2003) 2.53
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2004) 2.45
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology (2007) 2.27
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res (2004) 2.19
Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst (2003) 2.19
Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol (2010) 2.18
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 2.16
Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology (2004) 2.16
Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology (2003) 2.16
Chronic kidney disease in adolescent and adult patients with phenylketonuria. J Inherit Metab Dis (2012) 2.15
Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene (2005) 2.14
Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuver. Gastrointest Endosc (2005) 2.12
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology (2012) 2.12
Variants in CPA1 are strongly associated with early onset chronic pancreatitis. Nat Genet (2013) 2.10
Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer (2008) 2.08
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
StellaTUM: current consensus and discussion on pancreatic stellate cell research. Gut (2011) 2.07
Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol (2005) 2.04
Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis. Neoplasia (2005) 2.03
ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology (2012) 1.99
The Kaiser's cancer revisited: was Virchow totally wrong? Virchows Arch (2011) 1.96
Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg (2007) 1.94
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm? J Hepatol (2005) 1.90
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis. Nat Genet (2006) 1.90
Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene (2005) 1.89
Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology (2003) 1.86
Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell (2007) 1.86
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A (2010) 1.84
The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch (2006) 1.82
Narrow-band versus white-light high definition television endoscopic imaging for screening colonoscopy: a prospective randomized trial. Gastroenterology (2008) 1.76
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study. Endocr Relat Cancer (2012) 1.76
Microadenomatosis of the endocrine pancreas in patients with and without the multiple endocrine neoplasia type 1 syndrome. Am J Surg Pathol (2006) 1.71
Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch (2007) 1.70
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology (2012) 1.68
Lymphoepithelial cysts of the pancreas: a report of 12 cases and a review of the literature. Mod Pathol (2002) 1.65
Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology (2007) 1.65
Pancreatic fibrosis associated with age and ductal papillary hyperplasia. Virchows Arch (2005) 1.58
Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int (2011) 1.57
Glucocorticoids regulate barrier function and claudin expression in intestinal epithelial cells via MKP-1. Am J Physiol Gastrointest Liver Physiol (2013) 1.56
Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp1- and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem (2002) 1.56
Multiple endocrine neoplasia type 1 (MEN1): loss of one MEN1 allele in tumors and monohormonal endocrine cell clusters but not in islet hyperplasia of the pancreas. J Clin Endocrinol Metab (2006) 1.55
Ductuloinsular tumors of the pancreas: endocrine tumors with entrapped nonneoplastic ductules. Am J Surg Pathol (2004) 1.53
The majority of intestinal IgA+ and IgG+ plasmablasts in the human gut are antigen-specific. J Clin Invest (2011) 1.53
Biliary intraepithelial neoplasia: an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol (2007) 1.51
Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J Immunol (2007) 1.51
GISTogram: a graphic presentation of the growing GIST complexity. Virchows Arch (2013) 1.51
Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem (2003) 1.50
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. J Clin Endocrinol Metab (2007) 1.49
Data quality of the German screening colonoscopy registry. Endoscopy (2013) 1.48
Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res (2003) 1.48
Bombesin, but not amylin, blocks the orexigenic effect of peripheral ghrelin. Am J Physiol Regul Integr Comp Physiol (2006) 1.47
Cardiac surgery for carcinoid heart disease in 12 cases. Gen Thorac Cardiovasc Surg (2011) 1.46
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging (2003) 1.46
Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer (2011) 1.46
Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol (2004) 1.46
Autoregulation of Th1-mediated inflammation by twist1. J Exp Med (2008) 1.43
Antireflux 'barriers': problems with patient recruitment for a new endoscopic antireflux procedure. Eur J Gastroenterol Hepatol (2009) 1.43
The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement. Virchows Arch (2010) 1.42
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: biochemical markers. Neuroendocrinology (2009) 1.42
Cellular hamartoma resembling gastrointestinal stromal tumor: a solid tumor of the pancreas expressing c-kit (CD117). Mod Pathol (2005) 1.40
New device for the introduction of a circular stapler in laparoscopic gastric bypass surgery. Obes Surg (2006) 1.40
Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology (2007) 1.40
Association of COLIA1 Sp1 polymorphism with the effect of subcutaneously injected recombinant hGH in GH-deficient adults. Pharmacogenomics (2008) 1.39
Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation. Prostaglandins Other Lipid Mediat (2012) 1.38
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38